An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Top Cited Papers
- 16 December 2011
- Vol. 61 (7), 997-1006
- https://doi.org/10.1136/gutjnl-2011-301501
Abstract
Background and aims Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that may be triggered by enteric pathogens and has also been linked to alterations in the microbiota and the host immune response. The authors performed a detailed analysis of the faecal microbiota in IBS and control subjects and correlated the findings with key clinical and physiological parameters. Design The authors used pyrosequencing to determine faecal microbiota composition in 37 IBS patients (mean age 37 years; 26 female subjects; 15 diarrhoea-predominant IBS, 10 constipation-predominant IBS and 12 alternating-type IBS) and 20 age- and gender-matched controls. Gastrointestinal and psychological symptom severity and quality of life were evaluated with validated questionnaires and colonic transit time and rectal sensitivity were measured. Results Associations detected between microbiota composition and clinical or physiological phenotypes included microbial signatures associated with colonic transit and levels of clinically significant depression in the disease. Clustering by microbiota composition revealed subgroups of IBS patients, one of which (n=15) showed normal-like microbiota composition compared with healthy controls. The other IBS samples (n=22) were defined by large microbiota-wide changes characterised by an increase of Firmicutes-associated taxa and a depletion of Bacteroidetes-related taxa. Conclusions Detailed microbiota analysis of a well-characterised cohort of IBS patients identified several clear associations with clinical data and a distinct subset of IBS patients with alterations in their microbiota that did not correspond to IBS subtypes, as defined by the Rome II criteria.Keywords
This publication has 49 references indexed in Scilit:
- Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infectionJournal of Hospital Infection, 2011
- Antibiotic Therapy for the Irritable Bowel SyndromeThe New England Journal of Medicine, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationThe New England Journal of Medicine, 2011
- Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectivesMicrobiology, 2010
- Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferersBMC Gastroenterology, 2009
- Development of functional gastrointestinal disorders after Giardia lambliainfectionBMC Gastroenterology, 2009
- Small intestinal bacterial overgrowth in patients with irritable bowel syndromeGut, 2007
- Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic studyClinical Therapeutics, 2006
- Functional Bowel DisordersGastroenterology, 2006
- Post‐infectious irritable bowel syndrome in patients with Shigella infectionJournal of Gastroenterology and Hepatology, 2005